Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET

In this Part II review, as a complement to the Part I published in this supplement, the authors cover the imaging techniques that evaluates the Alzheimer's disease according to the different metabolic and molecular profiles. In this section MR spectroscopy, FDG-PET and amyloid PET are deeply discussed.

[1]  John Seibyl,et al.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.

[2]  Z. Ding,et al.  Longitudinal Progression of Cognitive Decline Correlates with Changes in the Spatial Pattern of Brain 18F-FDG PET , 2013, The Journal of Nuclear Medicine.

[3]  R. Vandenberghe,et al.  Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer’s disease , 2013, Alzheimer's & Dementia.

[4]  D. Silverman,et al.  FDG-PET in early AD diagnosis. , 2013, The Medical clinics of North America.

[5]  M. Mitka.  PET imaging for Alzheimer disease: are its benefits worth the cost? , 2013, JAMA.

[6]  Keith A. Johnson,et al.  Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association , 2013, The Journal of Nuclear Medicine.

[7]  C. Rowe,et al.  18F-florbetaben Aβ imaging in mild cognitive impairment , 2013, Alzheimer's Research & Therapy.

[8]  I. Buvat,et al.  A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology , 2012, Physics in medicine and biology.

[9]  P. Solomon,et al.  New Criteria for Alzheimer Disease and Mild Cognitive Impairment: Implications for the Practicing Clinician , 2012, The neurologist.

[10]  R. Armstrong.  Size frequency distributions of β-amyloid (Aβ) deposits: a comparative study of four neurodegenerative disorders. , 2012, Folia neuropathologica.

[11]  Janet S. Reddin,et al.  Feasibility of estimation of brain volume and 2-deoxy-2-(18)F-fluoro-D-glucose metabolism using a novel automated image analysis method: application in Alzheimer's disease. , 2012, Hellenic journal of nuclear medicine.

[12]  C. Rowe,et al.  Subacute Ischemic Stroke Is Associated With Focal 11C PiB Positron Emission Tomography Retention But Not With Global Neocortical A&bgr; Deposition , 2012, Stroke.

[13]  Nick C Fox,et al.  Brain imaging in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[14]  C. Rowe,et al.  Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  Juha Koikkalainen,et al.  Combination of Biomarkers: PET [18F]Flutemetamol Imaging and Structural MRI in Dementia and Mild Cognitive Impairment , 2012, Neurodegenerative Diseases.

[16]  A. Alavi,et al.  Amyloid-β imaging with PET in Alzheimer’s disease: is it feasible with current radiotracers and technologies? , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Keith A. Johnson,et al.  Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  David A Bennett,et al.  Correlation of Amyloid PET Ligand Florbetapir F 18 Binding With A&bgr; Aggregation and Neuritic Plaque Deposition in Postmortem Brain Tissue , 2012, Alzheimer disease and associated disorders.

[19]  N. Bohnen,et al.  Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature , 2012, The Journal of Nuclear Medicine.

[20]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[21]  Kewei Chen,et al.  Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. , 2011, Archives of neurology.

[22]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[23]  Alberto Pupi,et al.  PET/CT in diagnosis of dementia , 2011, Annals of the New York Academy of Sciences.

[24]  John Seibyl,et al.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.

[25]  S. Lehéricy,et al.  Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl‐11C]‐2‐(4′‐methylaminophenyl)‐ 6‐hydroxybenzothiazole , 2011, Annals of neurology.

[26]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[27]  C. Flask,et al.  A novel PET marker for in vivo quantification of myelination. , 2010, Bioorganic & medicinal chemistry.

[28]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[29]  Seong Jin Cho,et al.  Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG , 2010, NeuroImage.

[30]  James Robert Brašić,et al.  In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.

[31]  Mark A Mintun,et al.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. , 2009, Archives of neurology.

[32]  Kuncheng Li,et al.  Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and alzheimer disease , 2009, Acta radiologica.

[33]  Yue Feng,et al.  Molecular probes for imaging myelinated white matter in CNS. , 2008, Journal of medicinal chemistry.

[34]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[35]  N. Fayed,et al.  Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. , 2008, Academic radiology.

[36]  C. Jack,et al.  Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. , 2008, Radiology.

[37]  C. Rowe,et al.  Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease , 2008, Neuropsychologia.

[38]  N. Scolding,et al.  IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.

[39]  R. Bartha,et al.  High field 1H MRS of the hippocampus after donepezil treatment in Alzheimer disease , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[40]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[41]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[42]  K. Kantarci.  1H magnetic resonance spectroscopy in dementia. , 2007, The British journal of radiology.

[43]  V. Libri,et al.  PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. , 2007, Brain : a journal of neurology.

[44]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[45]  B. Miller,et al.  11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration , 2007, Neurology.

[46]  Nick C Fox,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.

[47]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[48]  N. Fox,et al.  Posterior Cingulate Neurometabolite Profiles and Clinical Phenotype in Frontotemporal Dementia , 2006, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[49]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[50]  D. Birchall,et al.  Proton magnetic resonance spectroscopy in frontotemporal dementia , 2006, Journal of Neurology.

[51]  M N Rossor,et al.  MRS shows abnormalities before symptoms in familial Alzheimer disease , 2006, Neurology.

[52]  Brian J Soher,et al.  A review of 1H MR spectroscopy findings in Alzheimer's disease. , 2005, Neuroimaging clinics of North America.

[53]  H. Kung,et al.  F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. , 2005, Journal of medicinal chemistry.

[54]  D. Auer,et al.  Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease , 2005, Neuroscience Letters.

[55]  N. Fayed,et al.  Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. , 2005, The American journal of psychiatry.

[56]  P. Renshaw,et al.  In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[57]  E G Tangalos,et al.  1H MR spectroscopy in common dementias , 2004, Neurology.

[58]  Randall S. Jones,et al.  1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia , 2004, Neurological research.

[59]  S. Chantal,et al.  Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease , 2004, Brain Research.

[60]  D. Silverman.  Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[61]  K. Herholz,et al.  Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[62]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[63]  Hirotoshi Ito,et al.  Posterior cingulate metabolic changes in frontotemporal lobar degeneration detected by magnetic resonance spectroscopy , 2004, Neuroradiology.

[64]  K Yaffe,et al.  Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD , 2003, Neurology.

[65]  E. Tangalos,et al.  Comparative Diagnostic Utility of Different MR Modalities in Mild Cognitive Impairment and Alzheimer’s Disease , 2002, Dementia and Geriatric Cognitive Disorders.

[66]  Kevin M Bradley,et al.  Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. , 2002, Brain : a journal of neurology.

[67]  A. Waldman,et al.  Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. , 2002, Archives of gerontology and geriatrics.

[68]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[69]  S. Chantal,et al.  Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. , 2002, Archives of neurology.

[70]  N. Schuff,et al.  Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD , 2002, Neurology.

[71]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[72]  P Sachdev,et al.  Magnetic resonance spectroscopy in AD , 2001, Neurology.

[73]  Activate your online subscription , 2000, Neurology.

[74]  G. Small.  Positron emission tomography imaging of dementia , 2000, Dialogues in clinical neuroscience.

[75]  F. Schmitt,et al.  Alzheimer neuropathologic alterations in aged cognitively normal subjects. , 1999, Journal of neuropathology and experimental neurology.

[76]  A. Waldman,et al.  Brain proton spectroscopy in dementia: an aid to clinical diagnosis , 1999, The Lancet.

[77]  G. Fein,et al.  Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease , 1997, Neurology.

[78]  P. Renshaw,et al.  Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. , 1997, The American journal of psychiatry.

[79]  T Ernst,et al.  Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. , 1997, Radiology.

[80]  W. Brooks,et al.  Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. , 1996, Archives of neurology.

[81]  G. Fein,et al.  Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. , 1996, Radiology.

[82]  T. Ernst,et al.  Abnormal cerebral metabolite concentrations in patients with probable alzheimer disease , 1994, Magnetic resonance in medicine.

[83]  A. Alavi,et al.  Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[84]  B D Ross,et al.  Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. , 1993, Radiology.

[85]  Habib Zaidi,et al.  Amyloid-β positron emission tomography imaging probes: a critical review. , 2013, Journal of Alzheimer's disease : JAD.

[86]  N. Fayed,et al.  Magnetic resonance imaging based clinical research in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[87]  C. Jack,et al.  11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .

[88]  G. Small,et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[89]  A. Rosenquist,et al.  Mapping of functional activity in brain with 18F-fluoro-deoxyglucose. , 1981, Seminars in nuclear medicine.